Panel Disdussion

More documents

Recommendations

Info

3rd International Congress 3rd International of Nuclear Congress Medicine of Nuclear & 15th Medicine Iranian Annual & 15th Iranian Congress Annual of Nuclear Congress Medicine of Nuclear Medicine Shahid Beheshti Shahid Beheshti University University of Medical Sciences of Medical 19-21 Sciences May 201119-21 May 2011 Synthesis and quality control of magnetic nanoparticles labeled 177Lu as a radiopharmaceutical agent for targeted cancer therapy Samira Rasaneh 1 , Hossein Rajabi 2 , Fariba Johari Daha 1 , Shahab Sheybani 1 1 Nuclear Science and Technology Research Institute 2 Tarbiat Modares University Introduction: Magnetic nanoparticles are good candidates used for the targeted drug delivery. They can be concentrated on a desired region, reducing collateral effects and improving the efficiency of therapy. In this paper we synthesized iron oxide nanoparticles as magnetic nanoparticles and labeled with 177Lutetium to produce a new radiopharmaceutical agent for targeted cancer therapy. Material and methods: Lutetium-177 was produced by bombarding 176Lu2O3 at a flux of 2.6—1014 n.Cm-2.S-1 for 10 days. Iron oxide nanoparticles were prepared using co-precipitation method. 177Luiron oxide nanoparticles was synthesized and all the quality control tests such as labeling yield, nanoparticle hydrodynamic and core size, stability up to 10 days, magnetization and cell toxicity was determined. Results: The good results of quality control tests indicated that 177Lu-iron oxide nanoparticles could be used for further investigation as a radiopharmaceutical agent in mice bearing tumor. The mean hydrodynamic size of the nanoparticles was 170±30 nm and the average core size was 120±25 nm. The Labeling yield was calculated 61±2%. On the average 86±5% of 177lu-iron oxide nanoparticles were stable in up to 10 days and no meaning changes were seen in nanoparticles size. This conjugation showed very good cytotoxcicity on cancer cells. Conclusion: We can conclude that 177Lu-iron oxide nanoparticles may be considered for further evaluation as a new radiopharmaceutical agent for targeted cancer therapy that needs more investigations. Keywords: magneticnanoparticles, 177Lutetium, drugdelivery, targetedcancertherapy 178
3rd International Congress of of Nuclear Medicine & & 15th 15th Iranian Annual Annual Congress of Congress of Nuclear Medicine Shahid Beheshti Shahid Beheshti University University of Medical of Medical Sciences Sciences 19-21 19-21 May May 2011 Biodistribution study of 177Lu- iron oxide nanoparticles in mice under an external magnetic field Samira Rasaneh 1 , Fariba Johari Daha 1 , Shahab Sheybani 1 , Shahram Akhlaghpoor 2 1 Nuclear Science and Technology Research Institute 2 Departments of Interventional Radiology Introduction: This study explored the possibility of utilizing iron oxide nanoparticles as a 177Lu delivery vehicle under an external magnetic field. In this study the biodistribution of 177Lu-iron oxide nanoparticles in mice with and without of an external magnetic field was considered. Material and methods: 177Lu-iron oxide nanoparticles were synthesized and all the quality control tests was performed. For the biodistribution study, female mice(n=24) were used. Before injection of 177Lu-iron oxide nanoparticles, an external magnetic field (magnetic flux density of 0.6 T) was positioned on the right feet of the mice, and it would persist in existence for 72 h. The mice were killed at 24, 48 and 72 h post-administration, tissues were removed and considered for 177Lu activities and iron concentration. This procedure was repeated without external magnetic field. Results: Comparison of the biodistribution results showed that 177Lu-iron oxide nanoparticles accumulated in the right feet of the mice more than other organs under the external magnetic field. The results indicated that the distribution of 177Lu-iron oxide nanoparticles was different with and without using magnetic field. Conclusion: The good biodistribution results accented that 177Luiron oxide nanoparticles may be considered for further evaluation as a new radiopharmaceutical agent for targeted cancer therapy that needs more investigations. Keywords: ironoxidenanoparticles, 177Lutetium, biodistribution, drugdelivery, cancertargetedtherapy 179
Page 1 and 2:
3rd International Congress of Nucle
Page 3 and 4:
Page 5 and 6:
Page 7 and 8:
3rd International Congress of of Nu
Page 9 and 10:
Page 11 and 12:
Page 13 and 14:
Page 15 and 16:
Page 17 and 18:
Page 19 and 20:
Page 21 and 22:
Page 23 and 24:
Page 25 and 26:
Page 27 and 28:
Page 29 and 30:
Page 31 and 32:
Page 33 and 34:
Page 35 and 36:
Page 37 and 38:
Page 39 and 40:
Page 41 and 42:
Page 43 and 44:
Page 45 and 46:
Page 47 and 48:
Page 49 and 50:
Page 51 and 52:
Page 53 and 54:
Page 55 and 56:
Page 57 and 58:
Page 59 and 60:
Page 61 and 62:
Page 63 and 64:
Page 65 and 66:
Page 67 and 68:
Page 69 and 70:
Page 71 and 72:
Page 73 and 74:
Page 75 and 76:
Page 77 and 78:
Page 79 and 80:
Page 81 and 82:
Page 83 and 84:
Page 85 and 86:
Page 87 and 88:
Page 89 and 90:
Page 91 and 92:
Page 93 and 94:
Page 95 and 96:
Page 97 and 98:
Page 99 and 100:
Page 101 and 102:
Page 103 and 104:
Page 105 and 106:
Page 107 and 108:
Page 109 and 110:
Page 111 and 112:
Page 113 and 114:
Page 115 and 116:
Page 117 and 118:
Page 119 and 120:
Page 121 and 122:
Page 123 and 124:
Page 125 and 126:
Page 127 and 128: 3rd International Congress of of Nu
Page 177: 3rd International Congress of of Nu
show all

Panel Disdussion

Create successful ePaper yourself

Delete template?

Save as template?